

DISCOVER: carDiovascular and renal outCOMes
in patients recoVERed from AKI – August 2024

FACTS:

- In Australia, the most common cause of kidney disease is diabetes, with about 5.5% (and increasing) of the population living with diabetes.
- AKI can occur when a person is already unwell with another health condition and is therefore common among people who are in hospital, increasing the burden (including cost) on the healthcare system.

PROJECT CYCLE:

2022–2025

PARTNERS:

The George Institute for Global Health

Australian Kidney Services

SUPPORTERS:

The George Institute for Global Health

National Heart Foundation of Australia

PRINCIPAL INVESTIGATOR:

A/Prof Ying Amanda Wang

BACKGROUND:

- Acute kidney injury (AKI) occurs when the kidneys do not work correctly. This can increase the risk of chronic kidney disease and heart disease, and lead to death.
- A drug called dapagliflozin has recently been shown to be useful in people who have chronic kidney disease by slowing its progression.
- It is unknown whether dapagliflozin provides a protective effect to people who show sufficient recovery of renal function from AKI.

AIM:

- Assess the feasibility of this trial.
- To determine whether participants, who have recently recovered sufficiently from AKI, can be recruited to this trial, remain in the trial until the end of the treatment and follow-up periods, and adhere to the treatment allocated.

METHODS:

- DISCOVER is a pilot, multicentre, feasibility, double-blind, parallel group, phase III, randomised control trial, involving two to five kidney services across Australia.
- Randomisation will be allocated equally to receive either 10mg dapagliflozin (intervention group) or placebo for 12 weeks, and followed up at six, 12 and 16 weeks post-randomisation.

IMPACT

- DISCOVER will provide further information about the use of dapagliflozin in people who have recently recovered from kidney disease, including the feasibility of future trials.



CONTACT:

To find out more about this project, its investigators or The George Institute please contact
Tina Wall +61 410 411 983 OR
twall@georgeinstitute.org.au

THE GEORGE INSTITUTE FOR GLOBAL HEALTH:

We're improving the lives of millions of people worldwide through innovative health research. Working across a broad health landscape, the Institute conducts clinical, population and health system research aimed at changing health practice and policy worldwide.